Nav: Home

Saiful Chowdhury named ASMS 'emerging investigator' for work linked to cancer, aging

April 20, 2017

The American Society of Mass Spectrometry has named Saiful Chowdhury, assistant professor of chemistry and biochemistry at The University of Texas at Arlington, as one of the leading emerging investigators worldwide for his work developing new techniques using mass spectrometry to differentiate protein modifications linked to cancer and aging.

Each of the 14 early researchers chosen are "already making important contributions in their respective fields of research and are influencing future directions in our field," according to the editorial published in the April 2017 Journal of the American Society of Mass Spectrometry, which includes the 2017 ASMS "Emerging Investigators" Focus.

UTA's Saiful Chowdhury has developed new strategies using mass spectrometry to identify prenylated proteins, or proteins modified by lipids, which are a biomarker of leukemia, pancreatic and colon cancers; genetic- and aging-related illnesses; and parasitic, bacterial and viral infections. Mass spectrometry identifies proteins or peptide, which are small pieces of protein, sequences by fragmenting them into smaller pieces and analyzing the masses.

"Identifying the modified proteins in a large sample with many unmodified proteins can be very difficult," Chowdhury said. "Our new technique, which we call mass spectrometry cleavable strategy, is an easy and inexpensive way to differentiate modified proteins by breaking the lipid bond selectively and using mass spectrometry to identify changes in mass."

The April 2017 focus edition of the Journal of the American Society of Mass Spectrometry also included a new article by Chowdhury in which he extends the application of his method using two major fragmentation techniques in tandem in gas phase to identify modified proteins.

The paper, titled "Gas-phase fragmentation behavior of oxidized prenyl peptides by CID and ETD Tandem Mass Spectrometry," explains how the Chowdhury lab is the first to use collision-based dissociation or CID and electron-transfer dissociation or ETD methods in tandem to identify oxidized lipid modified peptides by mass spectrometry.

"Gas-phase cleavable strategies are becoming my hallmark in this field," Chowdhury said. They produce fragment markers in the mass spectra so protein interactions and modifications can be pinpointed with high accuracy."

"Going forward, we plan to identify comprehensively the list of enzymes causing the lipid modifications so new inhibitors can be developed to target proteins within cancer treatments," he added.

Frederick MacDonnell, chair of UTA's Department of Chemistry and Biochemistry, underlined the importance of this research within the University's strategic focus on Health and the Human Condition within the Strategic Plan 2020: Bold Solutions|Global Impact.

"This study opens new avenues for a more efficient analysis of these modified proteins using mass spectrometry and will significantly improve our knowledge of the mechanism of cancer, cancer treatments and diagnosis, as well as other diseases," MacDonnell said.

"I would also like to congratulate Dr. Chowdhury on being recognized by the ASMS on an international level as a leading emerging investigator researcher in his field," he added.

About The University of Texas at Arlington

The University of Texas at Arlington is a Carnegie Research-1 "highest research activity" institution. With a projected global enrollment of close to 57,000, UTA is one of the largest institutions in the state of Texas. Guided by its Strategic Plan 2020 Bold Solutions|Global Impact, UTA fosters interdisciplinary research and education within four broad themes: health and the human condition, sustainable urban communities, global environmental impact, and data-driven discovery. UTA was recently cited by U.S. News & World Report as having the second lowest average student debt among U.S. universities. U.S. News & World Report lists UTA as having the fifth highest undergraduate diversity index among national universities. The University is a Hispanic-Serving Institution and is ranked as the top four-year college in Texas for veterans on Military Times' 2017 Best for Vets list.

University of Texas at Arlington

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

There's so much we've yet to explore–from outer space to the deep ocean to our own brains. This hour, Manoush goes on a journey through those uncharted places, led by TED Science Curator David Biello.
Now Playing: Science for the People

#556 The Power of Friendship
It's 2020 and times are tough. Maybe some of us are learning about social distancing the hard way. Maybe we just are all a little anxious. No matter what, we could probably use a friend. But what is a friend, exactly? And why do we need them so much? This week host Bethany Brookshire speaks with Lydia Denworth, author of the new book "Friendship: The Evolution, Biology, and Extraordinary Power of Life's Fundamental Bond". This episode is hosted by Bethany Brookshire, science writer from Science News.
Now Playing: Radiolab

Dispatch 2: Every Day is Ignaz Semmelweis Day
It began with a tweet: "EVERY DAY IS IGNAZ SEMMELWEIS DAY." Carl Zimmer – tweet author, acclaimed science writer and friend of the show – tells the story of a mysterious, deadly illness that struck 19th century Vienna, and the ill-fated hero who uncovered its cure ... and gave us our best weapon (so far) against the current global pandemic. This episode was reported and produced with help from Bethel Habte and Latif Nasser. Support Radiolab today at